» Articles » PMID: 38541851

Texture Features of F-Fluorodeoxyglucose Positron Emission Tomography for Predicting Programmed Death-Ligand-1 Levels in Non-Small Cell Lung Cancer

Abstract

Identifying programmed death-ligand-1 (PD-L1) expression is crucial for optimizing treatment strategies involving immune checkpoint inhibitors. However, the role of intratumoral metabolic heterogeneity specifically derived from F-fluorodeoxyglucose (FDG) positron emission tomography (PET) images in predicting PD-L1 expression in patients with newly diagnosed non-small cell lung cancer (NSCLC) remains unexplored. Here, we investigated the association between FDG PET texture features and PD-L1 expression by retrospectively analyzing the data of patients newly diagnosed with NSCLC who underwent FDG PET/CT scans and PD-L1 immunohistochemical staining before treatment. Patients were categorized based on their tumor proportion scores (TPSs) into negative-, low-, and high-PD-L1 expression groups. We computed the maximum standardized uptake value and 31 texture features for the primary tumor from PET images and compared differences in parameters among the groups. Of the 83 patients, 12, 45, and 26 were assigned to the negative-, low-, and high-PD-L1 expression groups, respectively. Six specific texture features (low gray-level run emphasis, short-run low gray-level emphasis, long-run high gray-level emphasis, low gray-level zone emphasis, high gray-level zone emphasis, and short-zone low gray-level emphasis) helped distinguish among all possible combinations. Our findings revealed that FDG PET texture features are potential imaging biomarkers for predicting PD-L1 expression in patients newly diagnosed with NSCLC.

References
1.
Zhou J, Zou S, Kuang D, Yan J, Zhao J, Zhu X . A Novel Approach Using FDG-PET/CT-Based Radiomics to Assess Tumor Immune Phenotypes in Patients With Non-Small Cell Lung Cancer. Front Oncol. 2021; 11:769272. PMC: 8635743. DOI: 10.3389/fonc.2021.769272. View

2.
Li J, Ge S, Sang S, Hu C, Deng S . Evaluation of PD-L1 Expression Level in Patients With Non-Small Cell Lung Cancer by F-FDG PET/CT Radiomics and Clinicopathological Characteristics. Front Oncol. 2022; 11:789014. PMC: 8716940. DOI: 10.3389/fonc.2021.789014. View

3.
Zhang M, Li G, Wang Y, Zhao S, Haihong P, Zhao H . PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis. Sci Rep. 2017; 7(1):10255. PMC: 5578960. DOI: 10.1038/s41598-017-10925-7. View

4.
Ishimura M, Norikane T, Mitamura K, Yamamoto Y, Manabe Y, Murao M . FDG PET texture indices as imaging biomarkers for epidermal growth factor receptor mutation status in lung adenocarcinoma. Sci Rep. 2023; 13(1):6742. PMC: 10130153. DOI: 10.1038/s41598-023-34061-7. View

5.
Zhang R, Hohenforst-Schmidt W, Steppert C, Sziklavari Z, Schmidkonz C, Atzinger A . Standardized 18F-FDG PET/CT radiomic features provide information on PD-L1 expression status in treatment-naïve patients with non-small cell lung cancer. Nuklearmedizin. 2022; 61(5):385-393. DOI: 10.1055/a-1816-6950. View